MedTrace Logo

Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction

NCT00302419 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2008-08-01

No results posted yet for this study

Summary

The investigators hypothesized that complementary intracoronary streptokinase administration to primary percutaneous intervention in patients with acute myocardial infarction may provide further improvement in myocardial perfusion by dissolving microvascular thrombus \[in situ formed or embolized from proximal site (spontaneous or following PCI)\] and fibrin.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

intracoronary infusion,

streptokinase, 250,000 units

PROCEDURE

primary percutaneous coronary angioplasty

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Murat Sezer, M.D. · Istanbul University, Istanbul School of Medicine

  • Sabahattin Umman, Prof. · Istanbul University, Istanbul School of Medicine

  • Taner Goren, Prof. · Istanbul University, Istanbul School of Medicine

  • Huseyin Oflaz, Assoc.Prof. · Istanbul University, Istanbul School of Medicine

  • Irem Okcular, M.D. · Istanbul University, Istanbul School of Medicine

  • Yılmaz Nisanci, Prof. · Istanbul University, Istanbul School of Medicine

  • Berrin Umman, Prof. · Istanbul University, Istanbul School of Medicine

  • Ahmet K Bilge, M.D. · Istanbul University, Istanbul School of Medicine

  • Mehmet Meric, Prof. · Istanbul University, Istanbul School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-02-28
Completion
2008-02-29

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302419 on ClinicalTrials.gov